ABX464-104
64 evidence topics · 6 sources
Objective
Purpose stated in the ClinicalTrials.gov record
Selected secondary objectives in the protocol, including cardiac function
Location and study date
Study dates in the ClinicalTrials.gov record
“Study Start (Actual) 2020-01-13” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2023-02-23” (opens the source at this quote in a new tab)
“Study Completion (Actual) 2023-02-23” (opens the source at this quote in a new tab)
“Results First Posted 2025-04-27” (opens the source at this quote in a new tab)
Registered locations
Centers and countries in the published report
Study design
Design details in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Primary purpose | “Treatment” |
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Model description | “open-label, follow-up study” |
| Masking | “None (Open Label)” |
| Phase | “Phase 2” |
| Enrollment (actual) | “217” |
Open-label design described in the ClinicalTrials.gov record
Entry regardless of induction response, continuation to week 96, and visit schedule
“Patients who had completed the induction study phase and who were willing to continue treatment could enter the OLM and receive treatment with obefazimod 50 mg od, regardless of the patient’s clinical response or randomized treatment (placebo or obefazimod 25, 50, or 100 mg od) during induction (Figure 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After week 48, patients who had shown clinical response (defined as a decrease in MMS ≥2 points and ≥30% from baseline (induction), plus a decrease in rectal bleeding subscore [RBS] ≥1 or an absolute RBS ≤1) were eligible for continued participation in the extension for a total period of 96 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“From day 1 onwards, patients were seen at the investigational site every 4 weeks up to week 48, then at weeks 60, 72, 84, and 96; flexible sigmoidoscopy with rectal and/or sigmoidal biopsies was performed at weeks 48 and 96 (both central and blinded reading of endoscopies were assessed).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety follow-up, exit for disease progression, and roll-over to ABX464-108 in the protocol
Data and Safety Monitoring Board and Independent Cardiovascular Safety Committee
Echocardiography added after enrollment was complete
Eligibility criteria
Inclusion criteria in the ClinicalTrials.gov record
Criteria for a second 48 weeks of treatment
Exclusion criteria in the ClinicalTrials.gov record
Induction population described in the published report
Treatment
Intervention in the ClinicalTrials.gov record
Administration in the protocol
Allowed and prohibited concomitant medications and corticosteroid tapering
“Allowed concomitant medications were continued from the baseline of the induction trial. These included corticosteroids (CS; ≤20 mg per day of prednisone or prednisone equivalent, ≤5 mg per day of beclomethasone dipropionate, or ≤9 mg per day budesonide MMX), oral 5-ASA, immunosuppressants such as azathioprine and 6-mercaptopurine, and antidiarrheals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The use of biologics (eg, TNF-α inhibitors, vedolizumab, ustekinumab), JAK inhibitors, cyclosporin, and tacrolimus was prohibited during the study. At the start of the OLM study, CS-tapering was recommended in all patients but was not mandatory.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using clinical remission by modified mayo score as the primary endpoint
Registered primary outcome measure
Primary endpoint and remission definition in the protocol
Efficacy endpoints and definitions in the published report
“Endpoints included rate of clinical remission (defined as stool frequency subscore [SFS] ≤1 and rectal bleeding = 0 and endoscopic score of 0 or 1), rate of clinical response (defined as a decrease from baseline in MMS ≥2 points and ≥30% from baseline, plus a decrease in RBS ≥1 or an absolute RBS ≤1), rate of endoscopic improvement (endoscopic subscore ≤1), rate of endoscopic remission (endoscopic subscore = 0), change from baseline of OLM study by visit up to week 96 for stool frequency, and fecal calprotectin (FCP).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CS-free status, defined as the cessation of CS for at least 12 weeks prior to each assessment time point in this analysis, was evaluated for efficacy outcomes at weeks 48 and 96 within the subgroup of patients receiving concomitant CS at the induction baseline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Glucocorticoid-free clinical remission defined in the protocol
Registered secondary outcome: clinical response definition
Endoscopic improvement and fecal calprotectin as treatment targets
“Endoscopically determined improvement in mucosal appearance has been associated with more favorable long-term outcomes in patients with UC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“FCP levels below 150 µg/g typically indicate remission with a high degree of accuracy according to Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE-II) recommendations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
No sample size calculation in the protocol
Participants enrolled and analyzed in the published report
“Of the 222 eligible patients who completed the induction trial, 217 (97.7%) were enrolled in the OLM study (Figure S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary analysis set for efficacy was the full analysis set (FAS, N = 217), and analysis of safety parameters was carried out using the safety analysis set (SAF, N = 217).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Description of analysis sets
Full analysis set, safety analysis set, baseline, and nonresponder imputation in the published report
“The FAS included all patients who received at least 1 dose of obefazimod 50 mg and had a baseline of OLM data for at least 1 efficacy variable; the SAF included all patients who received at least 1 dose of obefazimod 50 mg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Baseline of OLM was defined as the last non-missing measurement after induction (week 8 or 16) taken prior to the first dose of obefazimod 50 mg of the OLM study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The proportions of patients in clinical remission, clinical response, with endoscopic improvement, or endoscopic remission were summarized descriptively using nonresponder imputation (NRI) analysis at weeks 48 and 96 (patients with missing data were imputed as nonresponders).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Analysis sets in the protocol
Two baselines and missing data rules in the statistical analysis plan
Descriptive statistics and interim analysis at week 48
Results
Participant disposition
Discontinuations by year in the published report
“Of 222 eligible patients, 217 were enrolled and 164 (75.6%) completed week 96 of the OLM study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thirty of 217 (13.8%) discontinued prior to week 48, 6 patients did not meet eligibility criteria for the second year of treatment (did not achieve clinical response at week 48 or were unwilling to continue) and 17/181 (9.4%) patients discontinued between weeks 48 and 96. All discontinuations were considered as treatment failures for the NRI analysis of efficacy at weeks 48 and 96.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Enrollment and completion in the Form 20-F
Baseline characteristics
Demographic and baseline characteristics in the published report
Baseline characteristics described in the text of the published report
“At baseline of OLM, the mean age was 42.1 years; 61.3% of patients were men; 162 patients were randomized to 1–3 doses of obefazimod and 55 patients to placebo in the induction trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At baseline of OLM, 98 patients (45.2%) had prior inadequate response to biologics or JAK inhibitors (70 of these 98 (71.4%) patients had inadequate response to ≥2 biologics or JAK inhibitors), 119/217 patients (54.8%) were naive to biologics or JAK inhibitors and 120/217 patients (55.3%) were using concomitant corticosteroids (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy results
Clinical and endoscopic outcomes at weeks 48 and 96, all participants (nonresponder imputation)
“Among the 217 patients who enrolled in the OLM study and received 50 mg od oral dosing with obefazimod, 177/217 (81.6%) and 158/217 (72.8%) achieved clinical response at weeks 48 and 96, respectively, and 119/217 (54.8%) and 114/217 (52.5%) patients achieved clinical remission at weeks 48 and 96, respectively. Furthermore, 133/217 (61.3%) and 128/217 (59.0%) patients had endoscopic improvement at weeks 48 and 96, while 72/217 (33.2%) and 78/217 (35.9%) patients attained endoscopic remission at weeks 48 and 96, respectively (Figure 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary outcome in the posted results: clinical remission at week 48 (of 217)
| Outcome | Participants |
|---|---|
| Clinical remission at week 48 | “119” |
Week 48 and week 96 outcomes reported in the Form 20-F
Outcomes by clinical response at week 8 of induction
“Among the 124 patients with clinical response at week 8 of the induction trial, 82/124 (66.1%) and 74/124 (59.7%) achieved clinical remission at weeks 48 and 96, respectively (Figure 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among the 93 patients that did not achieve clinical response at week 8 of the induction trial, 37/93 (39.8%) and 40/93 (43.0%) achieved clinical remission at weeks 48 and 96, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Outcomes by induction treatment: obefazimod or placebo
“Overall, 162 patients treated with obefazimod during induction entered the OLM. Among this subgroup, 103/162 (63.6%) achieved clinical response at W8 of the induction trial, while 59/162 (36.4%) did not.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For example, clinical remission was achieved by 69/103 (67.0%) and 65/103 (63.1%) among W8 clinical responders at W48 and W96, respectively, compared to 20/59 (33.9%) and 24/59 (40.7%) among W8 nonresponders.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among the 55 patients receiving placebo during induction and entering the OLM, 21/55 (38.2%) achieved clinical response at W8 of the induction trial, while 34/55 (61.8%) did not. Clinical remission was achieved by 13/21 (61.9%) and 9/21 (42.9%) of W8 clinical responders at W48 and W96, respectively, compared to 17/34 (50.0%) and 16/34 (47.1%) of nonresponders.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Outcomes by previous biologic or JAK inhibitor exposure
“Among the 98 patients with inadequate response to biologics (anti-TNFα, vedolizumab, ustekinumab) or JAK inhibitors, 74/98 (75.5%) achieved clinical response at week 48 and 66/98 (67.3%) at week 96; 38/98 patients (38.8%) were in clinical remission at both weeks 48 and 96 (Figure 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among the 119 patients naïve to biologics or JAK inhibitors at the induction study baseline, 103/119 (86.6%) and 92/119 (77.3%) achieved a clinical response at weeks 48 and 96. In this subset, clinical remission was achieved by 81/119 patients (68.1%) at week 48 and by 76/119 patients (63.8%) at week 96” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Corticosteroid-free outcomes in participants receiving corticosteroids at induction baseline
“Among the 115 patients enrolled in the OLM who received concomitant CS at induction baseline, 64/115 (55.7%) were in clinical remission rates at week 48 and 60/115 (52.2%) at week 96. While the protocol did not require CS-tapering upon entry to the OLM study, 12-week CS-free clinical remission was attained by 43/115 patients (37.4%) at week 48 and by 40/115 patients (34.8%) at week 96.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Notably, among the patients that met clinical endpoints but not the corresponding CS-free clinical endpoints, many investigators chose not to attempt the optional CS-tapering.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fecal calprotectin
“The median FCP concentration decreased from 204.7 µg/g at baseline of OLM, to 86.6 µg/g at week 48 and 89.6 µg/g at week 96 (Table 2). Of the 167 patients with available data at week 48, 122/167 (73.1%) achieved FCP levels below 250 µg/g, and 109/167 (65.3%) achieved FCP levels below 150 µg/g. At week 96, 102 (69.4%) of the 147 patients with available data achieved FCP levels below 250 µg/g, and 91/147 (61.9%) achieved FCP levels below 150 µg/g.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
miR-124 expression in blood and rectal tissue
Comparison with week 8 induction results
“Efficacy rates increased during the maintenance treatment period with obefazimod 50 mg relative to week 8 of the induction trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At week 48 of the OLM study, these percentages increased to 82% for clinical response and 61% for endoscopic improvement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
IBDQ planned as a secondary endpoint in the protocol
Missing IBDQ scores not imputed in the statistical analysis plan
Stool frequency and rectal bleeding recorded in a paper diary
Safety results
Treatment-emergent adverse events over 96 weeks
“At least 1 TEAE was reported for 148 (68.2%) of 217 obefazimod-treated patients (Table 3). The most common TEAEs reported in at least 5% of patients were COVID-19 (14.3%), headache (11.5%), UC (7.8%), nasopharyngitis (6.9%), back pain (5.5%), and arthralgia (5.1%). TESAEs were reported by 18 patients (8.3%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was 1 malignant meningioma unrelated to treatment, and 1 death was reported, unrelated to treatment (car accident). TEAEs leading to study discontinuation were reported in 17 patients (7.8%) (Table 4). These events included the worsening of disease (coded as colitis ulcerative and colitis), which resulted in the discontinuation of 9 patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Infections and infestations TESAEs, reported for 4 patients, comprised COVID-19/COVID-19 pneumonia (2 patients, 1.0%), urosepsis (1 patient, 0.5%), and appendicitis (1 patient, 0.5%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Laboratory results revealed no new or unexpected safety signals, and there were no clinically meaningful changes in laboratory parameters compared to week 8.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Headache after switching dose at entry
“Ten of the 25 patients who reported headache experienced them within the first 7 days after switching from placebo to obefazimod or from 25 to 50 mg upon entering the OLM study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Headache appears to be associated with the introduction to obefazimod treatment, as the rate was reduced to 11.5% of patients who received up to 96 weeks obefazimod 50 mg compared to 30.2% of patients who received obefazimod 50 mg during induction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment-emergent adverse events leading to discontinuation
| Event | n (%) |
|---|---|
| Any TEAE | “17 (7.8)”View highlighted excerpt for this quote |
| Colitis ulcerative | “7 (3.2)”View highlighted excerpt for this quote |
| Colitis | “2 (0.9)”View highlighted excerpt for this quote |
| Ischemic stroke | “1 (0.5)”View highlighted excerpt for this quote |
| Left ventricular dysfunction | “1 (0.5)”View highlighted excerpt for this quote |
| Alanine aminotransferase increased | “1 (0.5)”View highlighted excerpt for this quote |
Adverse events in the posted results: participants affected / at risk (%)
| Event | ABX464 50 mg |
|---|---|
| All-cause mortality | “1/217 (0.46%)” |
| Serious adverse events, total | “18/217 (8.29%)” |
| Other adverse events, total | “148/217 (68.20%)” |
| COVID-19 | “31/217 (14.29%)” |
| Headache | “25/217 (11.52%)” |
| Colitis ulcerative | “17/217 (7.83%)” |
| Nasopharyngitis | “15/217 (6.91%)” |
Long-term safety: phase 2b open-label maintenance study through 96 weeks
“In total, 148/217 patients (68.2%) reported at least 1 treatment-emergent adverse event (TEAE).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most frequent TEAEs were COVID-19 (14.3%), headache (11.5%), UC (7.8%), and nasopharyngitis (6.9%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was 1 malignant meningioma unrelated to treatment, and 1 death was reported, unrelated to treatment (car accident).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“AESIs reported in more than 1 patient were headache, rash, and eczema, which were reported in 4 (1.8%), 3 (1.4%), and 2 patients (0.9%), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No new safety risks emerged over 96 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary
ABX464-104 was a single-group, open-label study without a control group, in which all 217 participants received obefazimod 50 mg once daily regardless of their induction treatment or response; the investigators state that “the results must be interpreted with caution due to the absence of a control group”. Entry into the second year required clinical response at week 48, and 6 participants did not continue because they did not achieve it or were unwilling. Efficacy was analyzed with nonresponder imputation, and the statistical analysis plan carried forward week 48 results for completers missing a week 96 assessment. Corticosteroid tapering was recommended and not mandatory; the protocol defined glucocorticoid-free clinical remission as no glucocorticoids for at least 8 weeks before week 48, and the published analysis used cessation for at least 12 weeks. Endpoint definitions differ between documents: the registry's week 48 outcome defines clinical response as a reduction in Mayo score of at least 3 points, while its week 48 continuation criterion and the publication use at least 2 points; the registry adds an at least 1-point decrease in stool frequency subscore to the clinical remission definition. At week 48, 177 of 217 participants had clinical response in the publication and the posted results, and the Form 20-F reports 178 (82%). The registry's detailed description states a 48-week treatment period and its arm description states 96 weeks. Echocardiography was added by amendment after enrollment was complete, without drug-free baseline measurements. Participants were enrolled at 69 centers in 14 countries in Europe and Canada, race and ethnicity were not collected, and 10 participants discontinued for “Other reason (e.g., Ukraine Crisis)”. The protocol planned IBDQ assessment at week 24 and week 48, and no IBDQ results were located in the publication or the posted results. Abivax personnel designed the trial with the principal academic investigators, and Abivax analyzed the data.
Limitations stated by the investigators
“Although the central evaluation of endoscopy data reduced the risk of bias in this open-label study, the results must be interpreted with caution due to the absence of a control group. Furthermore, steroid cycling was not accounted for in the NRI method, potentially limiting the interpretation of CS-free outcomes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CS-free efficacy rates might have been higher had CS-tapering been required during the OLM study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Role of the funder
“Personnel from Abivax designed the trial in conjunction with the principal academic investigators. A contract research organization collected the trial data, Abivax analyzed the data, and all of the authors jointly interpreted the data.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote